<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1665-1146</journal-id>
<journal-title><![CDATA[Boletín médico del Hospital Infantil de México]]></journal-title>
<abbrev-journal-title><![CDATA[Bol. Med. Hosp. Infant. Mex.]]></abbrev-journal-title>
<issn>1665-1146</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Salud, Hospital Infantil de México Federico Gómez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1665-11462016000100018</article-id>
<article-id pub-id-type="doi">10.1016/j.bmhimx.2015.11.009</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Primary immunodeficiencies and B-cell lymphomas]]></article-title>
<article-title xml:lang="es"><![CDATA[Inmunodeficiencias primarias y linfomas de células B]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martín-Mateos]]></surname>
<given-names><![CDATA[María Anunciación]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Piquer Gibert]]></surname>
<given-names><![CDATA[Mónica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Universidad de Barcelona Facultad de Medicina Hospital Universitario Sant Joan de Déu]]></institution>
<addr-line><![CDATA[Barcelona ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2016</year>
</pub-date>
<volume>73</volume>
<numero>1</numero>
<fpage>18</fpage>
<lpage>25</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1665-11462016000100018&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1665-11462016000100018&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1665-11462016000100018&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: In primary immunodeficiencies there is a failure in the anti-tumor defense. Common variable immunodeficiency (CVID) is one of the most common primary immunodeficiencies characterized by an alteration in the differentiation of B lymphocytes (BL). Epstein-Barr virus (EBV) is an ubiquitous virus that selectively infects the BL. In patients with immunodeficiency, uncontrolled proliferation of infected BL and the action of viral proteins promote the development of lymphomas.  Clinical cases: At the University Hospital Sant Joan de Deu, Barcelona, 28 patients were diagnosed with CVID from 2000 to 2013. This paper describes four patients who developed non-Hodgkin's lymphoma (NHL). The lymphoma was associated with EBV in two of the cases. Patients were &lt; 18 years old, diagnosed with lymphoma between 4 and 13 years old. Two patients were treated with rituximab as monotherapy and achieved complete remission. Two patients were treated with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) and radiotherapy or rituximab and achieved complete remission.  Conclusions: Early detection of EBV infections and NHL in all patients diagnosed with CVID is recommended, regardless of age at diagnosis.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: En las inmunodeficiencias primarias existe un fallo en la defensa antitumoral. La inmunodeficiencia variable común (IDVC) es una de las inmunodeficiencias primarias más frecuentes. Se caracteriza por una alteración en la diferenciación de linfocitos B (LB). El virus de Epstein-Barr (EBV) es un virus ubicuo que infecta de manera selectiva los LB. En pacientes con inmunodeficiencias, la proliferación incontrolada de LB infectados y la acción de proteínas virales promueve la aparición de linfomas.  Casos clínicos: En el Hospital Universitario Sant Joan de Déu, Barcelona, se han diagnosticado 28 pacientes con IDVC del 2000 al 2013. En este trabajo se describen cuatro que desarrollaron linfoma no Hodgkin (NHL). El linfoma fue asociado a EBV en dos de ellos. Los pacientes eran menores de 18 años, con el linfoma diagnosticado entre los 4 y 13 años de edad. Dos de los pacientes fueron tratados con rituximab como monoterapia, y lograron la remisión completa. Dos fueron tratados con CHOP (ciclofosfamida, doxorrubicina, vincristina y prednisolona) y radioterapia o rituximab y también alcanzaron la remisión completa.  Conclusiones: Se recomienda realizar la detección precoz de las infecciones por EBV y los NHL en todos los pacientes con diagnóstico de IDVC, independientemente de la edad del diagnóstico.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Inmunidad antitumoral]]></kwd>
<kwd lng="es"><![CDATA[Inmunodeficiencia variable común]]></kwd>
<kwd lng="es"><![CDATA[Linfomas B]]></kwd>
<kwd lng="es"><![CDATA[Linfoma no Hodgkin]]></kwd>
<kwd lng="es"><![CDATA[Virus Epstein-Barr]]></kwd>
<kwd lng="en"><![CDATA[Antitumor immunity]]></kwd>
<kwd lng="en"><![CDATA[Common variable immunodeficiency]]></kwd>
<kwd lng="en"><![CDATA[B lymphomas]]></kwd>
<kwd lng="en"><![CDATA[Non-Hodgkin's lymphoma]]></kwd>
<kwd lng="en"><![CDATA[Epstein-Barr virus]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martín-Mateos]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inmunodeficiencias primarias]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Moro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Málaga]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Madero]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<collab>Asociación Española de Pediatría</collab>
<source><![CDATA[Cruz, Tratado de Pediatría]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Médica Panamericana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Primary immunodeficiencies: a 27-year review at a tertiary paediatric hospital in Cape Town, South Africa]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Naidoo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ungerer]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pienaaer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Eley]]></surname>
<given-names><![CDATA[B S]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Immunol]]></source>
<year>2011</year>
<volume>31</volume>
<page-range>99-105</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martín-Mateos]]></surname>
<given-names><![CDATA[M.A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inmunodeficiencias secundarias]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Tratado de Pediatría]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Ergon]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Herz]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Boushifa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Casanova]]></surname>
<given-names><![CDATA[J L]]></given-names>
</name>
<name>
<surname><![CDATA[Chapel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Conley M]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cunningham-Rundless]]></surname>
<given-names><![CDATA[C.H]]></given-names>
</name>
</person-group>
<source><![CDATA[Front Immunol]]></source>
<year>2011</year>
<volume>2</volume>
<page-range>54</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Eurpean Society for Immunodeficiencies (ESID) members Patient-centered screening for primary immunodeficiency, a multi-stage diagnostic protocol designed for non-immunologists: 2011 update]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Vries]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Exp Immunol]]></source>
<year>2012</year>
<volume>167</volume>
<page-range>108-19</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="book">
<article-title xml:lang=""><![CDATA[Inmunología antitumoral]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abbas]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Lichtman]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Pillai]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Inmunología Celular y Molecular]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier Saunders]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Viruses associated with human cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[McLaughlin-Drubin]]></surname>
<given-names><![CDATA[M.E]]></given-names>
</name>
<name>
<surname><![CDATA[Munger]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Biochim Biophys Acta]]></source>
<year>2008</year>
<volume>1782</volume>
<page-range>127-50</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[An Epstein-Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[J.I]]></given-names>
</name>
<name>
<surname><![CDATA[Kieff]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[J Virol]]></source>
<year>1991</year>
<volume>65</volume>
<page-range>5880-5</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Second-site homologous recombination in Epstein-Barr virus insertion of type 1 EBNA 3 genes in place of type 2 has no effect on in vitro infection]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tomkinson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kieff]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[J Virol]]></source>
<year>1992</year>
<volume>66</volume>
<page-range>780-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Lymphoma as presentation of common variable immunodeficiency]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barón-Ruiz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Martín-Mateos]]></surname>
<given-names><![CDATA[M.A]]></given-names>
</name>
<name>
<surname><![CDATA[Plaza-Martín]]></surname>
<given-names><![CDATA[A.M]]></given-names>
</name>
<name>
<surname><![CDATA[Giner-Muñoz]]></surname>
<given-names><![CDATA[M.T]]></given-names>
</name>
<name>
<surname><![CDATA[Piquer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Allergol Immunopathol (Madr)]]></source>
<year>2009</year>
<volume>37</volume>
<page-range>51-3</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Non-Hodgkin lymphoma in pediatric patients with common variable immunodeficiency]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piquer Gibert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alsina]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Giner Muñoz]]></surname>
<given-names><![CDATA[M.T]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz Martínez]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz Echevarria]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Dominguez]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Pediatr]]></source>
<year>2015</year>
<volume>174</volume>
<page-range>1069-76</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quinti]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Soresina]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Spadaro]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Martino]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Donnanno]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Agostini]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Immunol]]></source>
<year>2007</year>
<volume>27</volume>
<page-range>308-16</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A Diagnóstico precoz de las inmunodeficiencias. Signos guía y pruebas complementarias orientativas para el pediatra]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martín Mateos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[An Pediatr Contin]]></source>
<year>2011</year>
<volume>9</volume>
<page-range>145-52</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Genome-wide association identifies diverse causes of common variable immunodeficiency]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Orange]]></surname>
<given-names><![CDATA[J.S]]></given-names>
</name>
<name>
<surname><![CDATA[Glessner]]></surname>
<given-names><![CDATA[J.T]]></given-names>
</name>
<name>
<surname><![CDATA[Resnick]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[K.E]]></given-names>
</name>
<name>
<surname><![CDATA[Lucas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ferry]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2011</year>
<volume>127</volume>
<page-range>1360-7</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Conley]]></surname>
<given-names><![CDATA[M.E]]></given-names>
</name>
<name>
<surname><![CDATA[Notarangelo]]></surname>
<given-names><![CDATA[L.D]]></given-names>
</name>
<name>
<surname><![CDATA[Etzioni]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Immunol]]></source>
<year>1999</year>
<volume>93</volume>
<page-range>190-7</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Common variable immunodeficiency disorders division into distinct clinical phenotypes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chapel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Lucas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bjorkander]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Webster]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Grimbacher]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood]]></source>
<year>2008</year>
<volume>112</volume>
<page-range>277-86</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Incidence of cancer in 98 patients with common varied immunodeficiency]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cunningham-Rundles]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Siegal]]></surname>
<given-names><![CDATA[F.P]]></given-names>
</name>
<name>
<surname><![CDATA[Cunningham-Rundles]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lieberman]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Immunol]]></source>
<year>1987</year>
<volume>7</volume>
<page-range>294-9</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vajdic]]></surname>
<given-names><![CDATA[C.M]]></given-names>
</name>
<name>
<surname><![CDATA[Mao]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[van Leeuwen]]></surname>
<given-names><![CDATA[M.T]]></given-names>
</name>
<name>
<surname><![CDATA[Kirkpatrick]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Grulich]]></surname>
<given-names><![CDATA[A.E]]></given-names>
</name>
<name>
<surname><![CDATA[Riminton]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood]]></source>
<year>2010</year>
<volume>116</volume>
<page-range>1228-34</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Review of gastric cancer risk factors in patients with common variable immunodeficiency disorders, resulting in a proposal for a surveillance programme]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dhalla]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[da Silva]]></surname>
<given-names><![CDATA[S.P]]></given-names>
</name>
<name>
<surname><![CDATA[Lucas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Travis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chapel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Exp Immunol]]></source>
<year>2011</year>
<volume>165</volume>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Lymphoma in common variable immunodeficiency interplay between immune dysregulation, infection and genetics]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chua]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Quinti]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Grimbacher]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr Opin Hematol]]></source>
<year>2008</year>
<volume>15</volume>
<page-range>368-74</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prospective study of cancer in patients with hypogammaglobulinaemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kinlen]]></surname>
<given-names><![CDATA[L.J]]></given-names>
</name>
<name>
<surname><![CDATA[Webster]]></surname>
<given-names><![CDATA[A.D]]></given-names>
</name>
<name>
<surname><![CDATA[Bird]]></surname>
<given-names><![CDATA[A.G]]></given-names>
</name>
<name>
<surname><![CDATA[Haile]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Peto]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Soothill]]></surname>
<given-names><![CDATA[J.F]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet]]></source>
<year>1985</year>
<volume>1</volume>
<page-range>263-6</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives a combined Danish and Swedish study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mellemkjaer]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hammarstrom]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Yuen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Heilmann]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Barington]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Exp Immunol]]></source>
<year>2002</year>
<volume>130</volume>
<page-range>495-500</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Characteristics of children with non-Hodgkin lymphoma associated with primary immune deficiency diseases: descriptions of five patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Emir]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Vezir]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Azkur]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Demir]]></surname>
<given-names><![CDATA[H.A]]></given-names>
</name>
<name>
<surname><![CDATA[Metin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Pediatr Hematol Oncol]]></source>
<year>2013</year>
<volume>30</volume>
<page-range>544-53</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Lymphoproliferative disease in antibody deficiency: a multi-centre study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gompels]]></surname>
<given-names><![CDATA[M.M]]></given-names>
</name>
<name>
<surname><![CDATA[Hodges]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lock]]></surname>
<given-names><![CDATA[R.J]]></given-names>
</name>
<name>
<surname><![CDATA[Angus]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Larkin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Exp Immunol]]></source>
<year>2003</year>
<volume>134</volume>
<page-range>314-20</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Possible role of human herpesvirus 8 in the lymphoproliferative disorders in common variable immunodeficiency]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wheat]]></surname>
<given-names><![CDATA[W.H]]></given-names>
</name>
<name>
<surname><![CDATA[Cool]]></surname>
<given-names><![CDATA[C.D]]></given-names>
</name>
<name>
<surname><![CDATA[Morimoto]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Rai]]></surname>
<given-names><![CDATA[P.R]]></given-names>
</name>
<name>
<surname><![CDATA[Kirkpatrick]]></surname>
<given-names><![CDATA[C.H]]></given-names>
</name>
<name>
<surname><![CDATA[Lindenbaum]]></surname>
<given-names><![CDATA[B.A]]></given-names>
</name>
</person-group>
<source><![CDATA[J Exp Med]]></source>
<year>2005</year>
<volume>202</volume>
<page-range>479-84</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The T cell response to persistent herpes virus infections in common variable immunodeficiency]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raeiszadeh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kopycinski]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Paston]]></surname>
<given-names><![CDATA[S.J]]></given-names>
</name>
<name>
<surname><![CDATA[Diss]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lowdell]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hardy]]></surname>
<given-names><![CDATA[G.A]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Exp Immunol]]></source>
<year>2006</year>
<volume>146</volume>
<page-range>234-42</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Lymphoid proliferations of indeterminate malignant potential arising in adults with common variable immunodeficiency disorders: unusual case studies and immunohistological review in the light of possible causative events]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[da Silva]]></surname>
<given-names><![CDATA[S.P]]></given-names>
</name>
<name>
<surname><![CDATA[Resnick]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lucas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lortan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cunningham-Rundles]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Immunol]]></source>
<year>2011</year>
<volume>31</volume>
<page-range>784-91</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Rituximab as monotherapy and in addition to reduced CHOP in children with primary immunodeficiency and non-Hodgkin lymphoma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shabbat]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Aharoni]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sarid]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ben-Harush]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kapelushnik]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Pediatr Blood Cancer]]></source>
<year>2009</year>
<volume>52</volume>
<page-range>664-6</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The therapeutic use of rituximab in non-Hodgkin's lymphoma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marcus]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hagenbeek]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Haematol Suppl]]></source>
<year>2007</year>
<page-range>5-14</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
